Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03214120 · ClinicalTrials.gov registry record

Does Modified Ultrafiltration Affect Thromboelastography Results?

A clinical trial of Congenital Heart Disease, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
40
Enrollment target
1
Study location

NCT03214120 is a study of Congenital Heart Disease that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03214120, a study of Congenital Heart Disease, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The study is to evaluate the effect of modified ultrafiltration on different components of Thromboelastography (TEG) in neonates undergoing cardiac surgery using cardiopulmonary bypass.

Conditions Studied

Study Locations (1)

Illinois

  • Advocate Children's Hospital - Oak Lawn

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-01-08
Est. Completion 2019-01-01

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT03214120

The ClinicalTrials.gov registry entry for NCT03214120 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03214120 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03214120 about?

NCT03214120 is a clinical study titled "Does Modified Ultrafiltration Affect Thromboelastography Results?". The study is to evaluate the effect of modified ultrafiltration on different components of Thromboelastography (TEG) in neonates undergoing cardiac surgery using cardiopulmonary bypass.

What is the current status of trial NCT03214120?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2018-01-08. Estimated completion is 2019-01-01.

What conditions does trial NCT03214120 study?

This clinical trial studies the following conditions: Congenital Heart Disease.

Who is sponsoring clinical trial NCT03214120?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03214120 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.